Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Benign Giant Cell Tumors Clear all

Completed Phase 3 Interventional Results available

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400

View directory record Official record

Conditions: Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions: Everolimus (RAD001), Everolimus Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 6
States / cities: Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated Feb 16, 2017 · Synced May 21, 2026, 7:40 PM EDT

Completed Phase 2 Interventional Results available

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

NCT00680992

View directory record Official record

Conditions: Cancer, Giant Cell Tumors, Giant Cell Tumor of Bone, Benign Giant Cell Tumors
Interventions: Denosumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older

Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 11
States / cities: Santa Monica, California • Stanford, California • Washington D.C., District of Columbia + 7 more

Source: ClinicalTrials.gov public record

Updated Sep 21, 2022 · Synced May 21, 2026, 7:40 PM EDT

Recruiting No phase listed Observational Accepts healthy volunteers

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

NCT05463796

View directory record Official record

Conditions: Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Interventions: Samples; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Not listed

Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Aug 6, 2025 · Synced May 21, 2026, 7:40 PM EDT